Calcium cycling proteins and heart failure: Mechanisms and therapeutics

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 46-52

  Marks, Andrew R ^a  

^a College of Physicians and Surgeons of Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7 METHOXY 4 METHYL 1,4 BENZOTHIAZEPINE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ION; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIURETIC AGENT; PHOSPHODIESTERASE INHIBITOR; RYANODINE RECEPTOR 1; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG;

CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CHANNEL GATING; DIURETIC THERAPY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE MUTATION; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT;

ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; CALCIUM CHANNELS; CALCIUM-BINDING PROTEINS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; MUSCLE PROTEINS; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHORYLATION; SARCOPLASMIC RETICULUM;

EID: 84873880957     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62834     Document Type: Review

References (65)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
2. Kamouh A, Francis GS. Kamouh A, Francis GS. Contemporary management and research directions in advanced heart failure: where are we going? Congest Heart Fail. 2011;17(5): 241-247.
3. Dube P, Weber KT. Congestive heart failure: pathophysiologic consequences of neurohormonal activation and the potential for recovery: part II. Am J Med Sci. 2011;342(6): 503-506.
4. Lompre AM, Hajjar RJ, Harding SE, Kranias EG, Lohse MJ, Marks AR. Ca2+ cycling and new therapeutic approaches for heart failure. Circulation. 2010;121(6): 822-830.
5. Marx SO, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101(4): 365-376.
6. Lehnart SE, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005;123(1): 25-35.
7. Shan J, et al. Role of chronic ryanodine receptor phosphorylation in heart failure and beta-adrenergic receptor blockade in mice. J Clin Invest. 2010; 120(12): 4375-4387.
8. Andersson DC, Marks AR. Fixing ryanodine receptor Ca leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov Today Dis Mech. 2010;7(2):e151-e157.
9. Lehnart SE, et al. Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest. 2008; 118(6): 2230-2245.
10. Lehnart SE, et al. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc Natl Acad Sci U S A. 2006; 103(20): 7906-7910.
11. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M. Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res. 1993;72(2): 463-469.
12. Morgan JP, Erny RE, Allen PD, Grossman W, Gwathmey JK. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation. 1990; 81(2 suppl):III21-III32.
13. Wehrens XH, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 2003;113(7): 829-840.
14. Hobai IA, O'Rourke B. Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation. 2001;103(11): 1577-1584.
15. Kushnir A, Marks AR. The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol. 2010;59: 1-30.
16. Ogrodnik J, Niggli E. Increased Ca(2+) leak and spatiotemporal coherence of Ca(2+) release in cardiomyocytes during beta-adrenergic stimulation. J Physiol. 2010;588(pt 1): 225-242.
17. Morimoto S, et al. Protein kinase A-dependent phosphorylation of ryanodine receptors increases Ca2+ leak in mouse heart. Biochem Biophys Res Commun. 2009;390(1): 87-92.
18. Blayney LM, Jones JL, Griffiths J, Lai FA. A mechanism of ryanodine receptor modulation by FKBP12/12.6, protein kinase A, and K201. Cardiovasc Res. 2010;85(1): 68-78.
19. Yano M, et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation. 2003;107(3): 477-484.
20. George CH, Higgs GV, Lai FA. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res. 2003; 93(6): 531-540.
21. Yano M, et al. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation. 2000;102(17): 2131-2136.
22. Ono K, et al. Altered interaction of FKBP12.6 with ryanodine receptor as a cause of abnormal Ca(2+) release in heart failure. Cardiovasc Res. 2000; 48(2): 323-331.
23. Doi M, et al. Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation. 2002;105(11): 1374-1379.
24. Estrada-Quintero T, Uretsky BF, Murali S, Griffith BP, Kormos RL. Neurohormonal activation and exercise function in patients with severe heart failure and patients with left ventricular assist system. A comparative study. Chest. 1995;107(6): 1499-1503.
25. Reiken S, et al. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J Biol Chem. 2003;278(1): 444-453.
26. Brillantes AB, et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506- binding protein. Cell. 1994;77(4): 513-523.
27. Reiken S, et al. PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J Cell Biol. 2003;160(6): 919-928.
28. Wehrens XH, et al. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci U S A. 2005;102(27): 9607-9612.
29. Reiken S, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 2003;107(19): 2459-2466.
30. Reiken S, et al. beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation. 2001;104(23): 2843-2848.
31. Kushnir A, Betzenhauser MJ, Marks AR. Ryanodine receptor studies using genetically engineered mice. FEBS Lett. 2010;584(10): 1956-1965.
32. Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci U S A. 2006;103(3): 511-518.
33. Huang F, Shan J, Reiken S, Wehrens XH, Marks AR. Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of heart failure by calstabin2 in mice. Proc Natl Acad Sci U S A. 2006; 103(9): 3456-3461.
34. Lehnart SE, et al. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation. 2004;109(25): 3208-3214.
35. Kaneko N, Matsuda R, Toda M, Shimamoto K. Inhibition of annexin V-dependent Ca2+ movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative. Biochim Biophys Acta. 1997;1330(1): 1-7.
36. Ito K, Shigematsu S, Sato T, Abe T, Li Y, Arita M. JTV-519, a novel cardioprotective agent, improves the contractile recovery after ischaemia-reperfusion in coronary perfused guinea-pig ventricular muscles. Br J Pharmacol. 2000;130(4): 767-776.
37. Kiriyama K, Kiyosue T, Wang JC, Dohi K, Arita M. Effects of JTV-519, a novel anti-ischaemic drug, on the delayed rectifier K+ current in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol. 2000;361(6): 646-653.
38. Kimura J, Kawahara M, Sakai E, Yatabe J, Nakanishi H. Effects of a novel cardioprotective drug, JTV- 519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol. 1999;79(3): 275-281.
39. Wehrens XH, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004;304(5668): 292-296.
40. Fauconnier J, et al. Ryanodine receptor leak mediated by caspase-8 activation leads to left ventricular injury after myocardial ischemia-reperfusion. Proc Natl Acad Sci U S A. 2011;108(32): 13258-13263.
41. Andersson DC, et al. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 2011;14(2): 196-207.
42. Fauconnier J, et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 2010;107(4): 1559-1564.
43. Bellinger AM, et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med. 2009;15(3): 325-330.
44. Shan J, et al. Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. J Clin Invest. 2010;120(12): 4388-4398.
45. Kobayashi S, et al. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model. Circ J. 2010;74(12): 2579-2584.
46. van der Werf C, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011; 57(22): 2244-2254.
47. Sheets MF, Fozzard HA, Lipkind GM, Hanck DA. Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med. 2010;20(1): 16-21.
48. Schultz Jel J, et al. Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am J Physiol Heart Circ Physiol. 2004;286(3):H1146-H1153.
49. Tavadia S, Authi KS, Hodgins MB, Munro CS. Expression of the sarco/endoplasmic reticulum calcium ATPase type 2 and 3 isoforms in normal skin and Darier's disease. Br J Dermatol. 2004; 151(2): 440-445.
50. Haghighi K, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111(6): 869-876.
51. Baker DL, et al. Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res. 1998;83(12): 1205-1214.
52. Chen Y, et al. Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reticulum Ca2+- ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation. 2004;109(15): 1898-1903.
53. del Monte F, et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A. 2004;101(15): 5622-5627.
54. Jessup M, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+- ATPase in patients with advanced heart failure. Circulation. 2011;124(3): 304-313.
55. Kohno M, et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol. 2003;284(3):H1035-H1042.
56. Antos CL, et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ Res. 2001;89(11): 997-1004.
57. George CH, Higgs GV, Mackrill JJ, Lai FA. Dysregulated ryanodine receptors mediate cellular toxicity: restoration of normal phenotype by FKBP12.6. J Biol Chem. 2003;278(31): 28856-28864.
58. Bers DM. Ryanodine receptor s2808 phosphorylation in heart failure: smoking gun or red herring. Circ Res. 2012;110(6): 796-799.
59. Marks AR. A guide for the perplexed: towards an understanding of the molecular basis of heart failure. Circulation. 2003;107(11): 1456-1459.
60. Timerman AP, et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem. 1996; 271(34): 20385-20391.
61. Timerman AP, Jayaraman T, Wiederrecht G, Onoue H, Marks AR, Fleischer S. The ryanodine receptor from canine heart sarcoplasmic reticulum is associated with a novel FK-506 binding protein. Biochem Biophys Res Commun. 1994;198(2): 701-706.
62. Hoch B, et al. Differentiation-dependent expression of cardiac delta-CaMKII isoforms. J Cell Biochem. 1998;68(2): 259-268.
63. Ling H, et al. Requirement for Ca2+/calmodulindependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest. 2009;119(5): 1230-1240.
64. Respress JL, et al. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res. 2012;110(11): 1474-1483.
65. Kushnir A, Shan J, Betzenhauser MJ, Reiken S, Marks AR. Role of CaMKIIdelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. Proc Natl Acad Sci U S A. 2010;107(22): 10274-10279.